(0%) 0 points
(0%) 0 points
(0%) 0 points
(0%) $0
(0%) $0
(0%) $0
(0%) $0
(0%) $0
(0%) $0
(0%) $0
(0%) $0
(0%) $0
Live Chart Being Loaded With Signals
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U...
Stats | |
---|---|
本日の出来高 | 0 |
平均出来高 | 0 |
時価総額 | 0 |
EPS | $0 ( 2024-02-08 ) |
次の収益日 | ( $-0.0600 ) 2024-05-09 |
Last Dividend | $0.0700 ( 2014-04-28 ) |
Next Dividend | $0 ( N/A ) |
P/E | 0 |
ATR14 | $0 (0.00%) |
Veru Inc 相関
10 最も負の相関 | |
---|---|
LWAC | -0.95 |
FANH | -0.894 |
AGFS | -0.892 |
IMRA | -0.883 |
TGLS | -0.867 |
PTMN | -0.864 |
USLB | -0.862 |
LYTS | -0.859 |
SLGN | -0.856 |
SEDG | -0.852 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Veru Inc 財務諸表
Annual | 2023 |
収益: | $16.30M |
総利益: | $7.57M (46.43 %) |
EPS: | $-1.100 |
FY | 2023 |
収益: | $16.30M |
総利益: | $7.57M (46.43 %) |
EPS: | $-1.100 |
FY | 2022 |
収益: | $39.35M |
総利益: | $30.59M (77.73 %) |
EPS: | $-1.050 |
FY | 2021 |
収益: | $61.26M |
総利益: | $47.93M (78.24 %) |
EPS: | $0.100 |
Financial Reports:
No articles found.
Veru Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0500 | 2010-01-27 |
Last Dividend | $0.0700 | 2014-04-28 |
Next Dividend | $0 | N/A |
Payout Date | 2014-05-07 | |
Next Payout Date | N/A | |
# dividends | 18 | -- |
Total Paid Out | $1.040 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.68 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2010 | $0.200 | 4.14% |
2011 | $0.200 | 3.50% |
2012 | $0.230 | 4.87% |
2013 | $0.270 | 3.69% |
2014 | $0.140 | 1.67% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -4.05 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.801 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -2.14 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.21 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 2.58 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.44 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.133 | -1.500 | 7.78 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -36.67 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.591 | 2.00 | -0.197 | -0.394 | [0 - 30] |
freeCashFlowPerShareTTM | -0.595 | 2.00 | -0.298 | -0.595 | [0 - 20] |
debtEquityRatioTTM | 0.208 | -1.500 | 9.17 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.503 | 1.000 | 4.95 | 4.95 | [0.2 - 0.8] |
operatingProfitMarginTTM | -3.96 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -5.53 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.198 | 0.800 | -2.02 | -1.612 | [0.5 - 2] |
Total Score | -1.265 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -1.980 | 1.000 | -0.301 | 0 | [1 - 100] |
returnOnEquityTTM | -2.14 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.595 | 2.00 | -0.198 | -0.595 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.591 | 2.00 | -0.197 | -0.394 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.416 | 1.500 | -0.561 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -3.74 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.19 |
Veru Inc
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。